Coronavirus / COVID

Simulations suggest deaths from COVID-19 could be cut in half if 80% of eligible patients took the antiviral therapy.

A retrospective study indicated higher rates of neurodevelopmental abnormalities in areas such as motor function and speech and language during the first year among babies born to women who had experienced a COVID-19 infection during pregnancy.

Vilobelimab (Gohibic) was granted Emergency Use Authorization to treat adults hospitalized with severe COVID-19 infection.

COVID-19 prevention practices such as masking, social distancing, and school closures lowered children’s exposures to circulating respiratory viruses and other environmental triggers of asthma.

A novel "antibody-mimetic" molecule administered intranasally in animal model prevented coronavirus infection from older, current and emerging variants.

These findings suggest the World Health Organization's definition of post-COVID-19 condition (long COVID) may be too broad.

Ensitrelvir is an investigational 3CL protease inhibitor that reduced COVID-19 illness duration by 1 day.

This study examined the impact of COVID-19 vaccination and infection on the risk of cardiac and all-cause mortality in young people aged 12-29 years.

Because trust in science predicts willingness to get a COVID-19 vaccine, the results of this study have significant public health consequences.

Early treatment with nirmatrelvir-ritonavir (Paxlovid) was associated with the greatest clinical benefit in reducing COVID-19 hospitalization and death.

The findings of this study are consistent with other findings that maternal viral infection during pregnancy increases the risk for neurodevelopmental morbidity in offspring.

When given within 5 days of COVID-19 symptoms, Paxlovid appeared to reduce risk for developing Post-COVID-19 Conditions (PCC).

A new study found negative expectations prior to COVID-19 vaccination were associated with more systemic adverse events in individuals receiving their second dose of a COVID-19 vaccine.

A midsized study demonstrated no therapeutic benefit to patients with mild-to-moderate COVID-19 taking this class of anthelmintics.

"Antibiotics can safely be withheld in most patients with viral respiratory infections,” these study authors wrote.

Risk factors for VTE among COVID-19 patients included age greater than 55 years, male gender, a history of thrombophilia, and obesity.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

A new study reveals how US states fared, and some of the underlying reasons why the pandemic has played out in vastly different ways.

A new study shows vaccination decreased the chances of developing the debilitating condition by nearly half.

Exposure to a common seasonal coronavirus stimulates a memory T cell response that protects children against COVID-19. However, this immune response peaks at age 6.

Despite failing to meet primary trial endpoints, molnupiravir reduced the length of COVID-19 infection by 4.2 days in vaccinated patients.

Yesterday, the FDA took a major step toward officially approving Paxlovid. Catch up on this story and the other top COVID-19 news updates from the past week.

The FDA's Antimicrobial Drugs Advisory Committee recommended approving Pfizer’s New Drug Application for Paxlovid to treat mild-to-moderate COVID-19 in adults at high risk of severe or fatal disease progression.

These investigators concluded Omicron XBB.1.5 the most successful COVID-19 variant of its lineage.

With this FDA emergency use authorization (EUA), all persons 6 months and older are now eligible to receive the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent booster.